Welcome to our dedicated page for Achilles Therapeutics Plc news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc stock.
Achilles Therapeutics plc (ACHL) is a clinical-stage biopharmaceutical company that has focused on AI-powered precision T cell therapies targeting clonal neoantigens in solid tumors. News about Achilles provides insight into how the company has developed and adjusted its programs, platforms, collaborations, and corporate structure over time.
Company announcements have covered clinical updates from its CHIRON and THETIS Phase I/IIa trials in advanced non-small cell lung cancer and recurrent or metastatic melanoma, including data on clonal neoantigen-reactive T cells (cNeT), enhanced host conditioning, and the performance of its VELOS manufacturing process. Releases have also described translational science findings related to tumor evolution, immune evasion, and neoantigen selection using the PELEUS bioinformatics platform.
Investors and researchers following ACHL can find news on strategic collaborations, such as the research collaboration with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines based on clonal neoantigens. Additional updates have detailed the sale of technology assets and data from the TRACERx NSCLC study and the Material Acquisition Platform (MAP) to AstraZeneca, marking significant changes in the company’s asset base and focus.
Recent corporate news has included strategic reviews, the discontinuation of the TIL-based cNeT program, closure of the CHIRON and THETIS trials, workforce and governance changes, and steps related to Nasdaq listing status. These include Nasdaq deficiency notices, a transfer to the Nasdaq Capital Market, and later, the company’s stated intention to voluntarily delist its ADSs and pursue a members’ voluntary liquidation. This news page aggregates such releases so readers can follow the evolution of Achilles Therapeutics’ clinical efforts, partnerships, financial updates, and planned wind-down.
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, announced its CEO Iraj Ali will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 9:30 a.m. ET. This event highlights the company's work in developing precision T cell therapies targeting clonal neoantigens for treating solid tumors, with ongoing trials for non-small cell lung cancer and melanoma. A webcast of the presentation will be available on their website.
Achilles Therapeutics (NASDAQ: ACHL) announces the appointment of Julie O’Neill as a Non-Executive Director and Markwin Velders, Ph.D. to its Scientific Advisory Board. O’Neill brings over 20 years of experience from companies like Alexion Pharmaceuticals and Gilead Sciences, emphasizing the importance of operations as the firm expands manufacturing capacity. Dr. Velders has significant experience in cell therapy, previously at Kite Pharma. Additionally, Rogier Rooswinkel will resign from the Board before the annual general meeting on June 28, 2021.
Achilles Therapeutics (NASDAQ: ACHL) presented a patient case study from its Phase I/IIa THETIS trial for metastatic melanoma at the AACR Annual Meeting 2021. The study highlighted insights into clonal neoantigen T cells (cNeT) post-dosing. The data demonstrated a significant polyclonal response, indicating the potential for a reproducible potency assay. The case involved a patient who received an immunotherapy combination halted due to toxicity, showing 53% of T cells in the manufactured product were reactive to their clonal neoantigens. Achilles focuses on precision T cell therapies targeted at unique cancer markers.
Achilles Therapeutics (NASDAQ: ACHL) has successfully completed its IPO, raising approximately $175.5 million by offering 9,750,000 American Depositary Shares at $18.00 each. This event marks a significant step for the company as it develops precision T cell therapies targeting clonal neoantigens for treating solid tumors. The offering was managed by major financial institutions including J.P. Morgan and BofA Securities. Proceeds are expected to support ongoing clinical trials.
Achilles Therapeutics (NASDAQ: ACHL) has announced its initial public offering (IPO), pricing 9,750,000 American Depositary Shares (ADSs) at $18.00 each, raising total gross proceeds of $175.5 million. The offering will close on April 6, 2021, and the ADSs are set to begin trading on March 31, 2021. Underwriters have a 30-day option to purchase an additional 1,462,500 ADSs. Achilles is focused on precision T cell therapies targeting cancer-specific neoantigens and is currently running two Phase I/IIa clinical trials.